136 related articles for article (PubMed ID: 31703643)
1. Less micrometastatic risk related to circulating tumor cells after endoscopic breast cancer surgery compared to open surgery.
Li S; Yan W; Yang X; Chen L; Fan L; Liu H; Liu K; Zhang Y; Jiang J
BMC Cancer; 2019 Nov; 19(1):1070. PubMed ID: 31703643
[TBL] [Abstract][Full Text] [Related]
2. Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR.
Park HS; Han HJ; Lee S; Kim GM; Park S; Choi YA; Lee JD; Kim GM; Sohn J; Kim SI
Yonsei Med J; 2017 Jan; 58(1):19-26. PubMed ID: 27873491
[TBL] [Abstract][Full Text] [Related]
3. Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse.
Saloustros E; Perraki M; Apostolaki S; Kallergi G; Xyrafas A; Kalbakis K; Agelaki S; Kalykaki A; Georgoulias V; Mavroudis D
Breast Cancer Res; 2011 Jun; 13(3):R60. PubMed ID: 21663668
[TBL] [Abstract][Full Text] [Related]
4. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
5. Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy.
Wang HY; Ahn S; Kim S; Park S; Park S; Han H; Sohn JH; Kim S; Lee H
Exp Mol Pathol; 2014 Dec; 97(3):445-52. PubMed ID: 25217799
[TBL] [Abstract][Full Text] [Related]
6. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
[TBL] [Abstract][Full Text] [Related]
7. Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer.
Goodman CR; Seagle BL; Friedl TWP; Rack B; Lato K; Fink V; Cristofanilli M; Donnelly ED; Janni W; Shahabi S; Strauss JB
JAMA Oncol; 2018 Aug; 4(8):e180163. PubMed ID: 29800954
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
10. Detection of circulating tumor cells in breast cancer patients using multiplex reverse transcription-polymerase chain reaction and specific primers for MGB, PTHRP and KRT19 correlation with clinicopathological features.
Skondra M; Gkioka E; Kostakis ID; Pissimissis N; Lembessis P; Pectasides D; Koutsilieris M
Anticancer Res; 2014 Nov; 34(11):6691-9. PubMed ID: 25368276
[TBL] [Abstract][Full Text] [Related]
11. A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer.
Politaki E; Agelaki S; Apostolaki S; Hatzidaki D; Strati A; Koinis F; Perraki M; Saloustrou G; Stoupis G; Kallergi G; Spiliotaki M; Skaltsi T; Lianidou E; Georgoulias V; Mavroudis D
Cell Physiol Biochem; 2017; 44(2):594-606. PubMed ID: 29161698
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the effect of surgery on the kinetics of circulating tumour cells in patients with operable breast cancer based on cytokeratin-19 mRNA detection.
Daskalakis M; Mavroudis D; Sanidas E; Apostolaki S; Askoxylakis I; de Bree E; Georgoulias V; Melissas J
Eur J Surg Oncol; 2011 May; 37(5):404-10. PubMed ID: 21376504
[TBL] [Abstract][Full Text] [Related]
13. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients.
Yoon SO; Kim YT; Jung KC; Jeon YK; Kim BH; Kim CW
Lung Cancer; 2011 Feb; 71(2):209-16. PubMed ID: 20471712
[TBL] [Abstract][Full Text] [Related]
14. KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients.
Wang XM; Zhang Z; Pan LH; Cao XC; Xiao C
Breast Cancer Res Treat; 2019 Apr; 174(2):375-385. PubMed ID: 30535933
[TBL] [Abstract][Full Text] [Related]
15. Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer.
Tryfonidis K; Kafousi M; Perraki M; Apostolaki S; Agelaki S; Georgoulias V; Stathopoulos E; Mavroudis D
Clin Breast Cancer; 2014 Dec; 14(6):442-50. PubMed ID: 24958324
[TBL] [Abstract][Full Text] [Related]
16. [mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR].
Zheng HY; Chen Q; Ye YB; Huang WW
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(32):2267-70. PubMed ID: 19087676
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells before and during follow-up after breast cancer surgery.
van Dalum G; van der Stam GJ; Tibbe AG; Franken B; Mastboom WJ; Vermes I; de Groot MR; Terstappen LW
Int J Oncol; 2015 Jan; 46(1):407-13. PubMed ID: 25339612
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.
Ignatiadis M; Litière S; Rothe F; Riethdorf S; Proudhon C; Fehm T; Aalders K; Forstbauer H; Fasching PA; Brain E; Vuylsteke P; Guardiola E; Lorenz R; Pantel K; Tryfonidis K; Janni W; Piccart M; Sotiriou C; Rack B; Pierga JY
Ann Oncol; 2018 Aug; 29(8):1777-1783. PubMed ID: 29893791
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
20. Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer.
Kuniyoshi RK; Gehrke Fde S; Alves BC; Vilas-Bôas V; Coló AE; Sousa N; Nunes J; Fonseca FL; Del Giglio A
Tumour Biol; 2015 Sep; 36(10):8075-83. PubMed ID: 25976504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
